SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Yang who started this subject8/29/2000 1:18:47 AM
From: manfredhasler  Read Replies (1) of 656
 
Some milestones on Immunex's product development

thanks to ny_wahoo on Yahoo!

Paine Webber report dtd 8/23/2000...
by: ny_wahoo 8/28/00 11:34 am
Msg: 13700 of 13720

highlights upcoming milestones:
1. market launch of Novantrone for secondary-progressive MS...Q3 2000
2. initiation of additional Phase II clinical studies of Nuvance in asthma ...Q3 2000
3. initiation of Phase II clinical study of Enbrel in psoriasis... Q3 2000
4. Additional clinical data on Enbrel at ACR...November 2000
5. Results from Phase III clinical study of Enbrel in psoriatic arthritis... Q1 2001
6. Initiation of Phase I clinical study of TRAIL/Apo2L in cancer...Q2 2001
7. BLA filing of Enbrel in psoriatic arthritis...Q2/Q3 2001
8. results of Phase III studies of Enbrel in chronic heart failure...Late 2001/early 2002.

Report also contains some encouraging news about future pipeline products, particularly ABX-EGF, Mobista and Avrend for various cancers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News